Advanced Enzyme Technologies is a research-driven manufacturer that turns naturally occurring proteins and live microorganisms into products that replace harsh chemicals - in medicines, food, animal feed and industrial processes. Founded in 1989 as Advanced Biochemicals, it grew from a single fermentation plant in Sinnar into India’s largest enzyme company through three decades of in-house R&D and a series of acquisitions that added manufacturing scale, European technology and a US distribution network. The recurring approach is to develop proprietary enzyme and probiotic strains in its own labs, prove their safety with regulators on multiple continents, then manufacture them at low cost in India for customers in 45-plus countries - a model that makes it one of the lowest-cost producers globally while holding 400-plus proprietary products. # Business segments Four engines built on the same fermentation and R&D backbone - a human-health anchor that supplies pharmaceutical and nutraceutical companies worldwide, an animal-nutrition business that replaces antibiotics in feed, an industrial-processing unit that swaps chemicals for enzymes in food and textiles, and a specialised manufacturing arm that turns powders into fast-dissolving tablets for other brands. ## 1. Human Nutrition: the pharmaceutical and nutraceutical engine **Enzymes and probiotics sold as active ingredients to health-capsule makers, sports-nutrition brands and API manufacturers - the company’s largest business, built on a blockbuster anti-inflammatory enzyme and a growing portfolio of clinically studied strains.** - **A single enzyme anchors the segment** - Serratiopeptidase, an anti-inflammatory, accounted for 23% of annual sales in FY26, and the company leads the Indian market for it. That concentration creates a dependable revenue core from which the rest of the portfolio is funded. - **Probiotics with regulatory clearance** - proprietary strains branded SEBtilis™ and SEBclausii™ have received GRAS (Generally Recognised as Safe) dossiers and “no question letters” from the US FDA, meaning they can be sold into the American supplement market without further safety hurdles. Two of its probiotic-and-enzyme supplements were listed by the US National Institutes of Health for proven efficacy against COVID-related fatigue, and the company won an NIH grant for that work. - **Enzymes that replace chemical steps in drug-making** - the biocatalysis sub-segment engineers enzymes that are solvent-proof and highly specific, so API manufacturers can cut the number of chemical steps, reduce energy use and lower solvent concentrations when producing intermediates for anti-cholesterol or anti-depressant drugs. - **A small direct-to-consumer toehold** - in India the company launched the B2C brand Wellfa in 2023, selling immune, gut-health and weight-management products online, while in the US it runs a direct-to-consumer business that contributed $1.29 million in a single quarter. The consumer business is tiny relative to the B2B engine but gives the company a direct read on end-user demand. ## 2. Industrial Bio-processing: replacing chemicals in factories and food plants **Enzymes that do the same job as industrial chemicals - clarifying juice, softening bread, fading jeans - while saving energy, water and waste.** - **Food enzymes that improve what a factory can sell** - the company makes enzymes for baking, dairy, brewing, fruit-and-vegetable processing and oil extraction, helping manufacturers create chemical-free baked goods, reduce sugar in biscuits and cakes, or extract more oil from the same raw material. The food-processing sub-segment grew 20% year-on-year in the final quarter of FY26. - **Textile and leather enzymes that cut pollution** - instead of using harsh chemicals to fade denim or process leather, the company’s non-food enzymes let mills save water and raw materials while reducing the effluent load that treatment plants must handle. The same enzymatic approach is sold into detergent makers and paper-and-pulp plants. - **A global baking push** - the company is confident enough in its baking-enzyme performance that it is actively expanding those solutions into Europe, the Americas and the rest of the world, having received positive feedback on product efficacy. ## 3. Animal Nutrition: enzymes and probiotics that replace antibiotics in feed **Feed-additive enzymes that help poultry and cattle extract more nutrition from the same feed, plus probiotics that promote growth without antibiotics - a segment where Asia is the growth engine.** - **Better digestion, lower feed cost** - enzymes such as cellulase and hemicellulase break down fibre in silage and corn-soy feeds, improving nutrient absorption so farmers can reduce feed quantity or switch to cheaper ingredients without sacrificing animal growth. - **Probiotics as an antibiotic alternative** - the company has launched non-armoured probiotics that can be used alongside antibiotics in feed, and is developing probiotic-postbiotic-prebiotic combinations for immunity and digestion. This matters because regulators and consumers are pushing livestock producers to cut antibiotic use. - **Geographic expansion underway** - growth in FY26 for the Animal Healthcare segment was driven mainly by increased sales in Asia, and the company is now building out sales and marketing teams in the USA, MENA and Asian markets while appointing more distributors overseas. ## 4. Specialised Manufacturing: contract manufacturing of fast-dissolving tablets **A separate factory business that turns enzyme and nutraceutical powders into effervescent tablets and granules for other brands - acquired, not built, and run by its original promoters.** - **Bought in 2021 to add a new capability** - the company acquired a 51% stake in SciTech Specialities, a contract manufacturer that uses aqueous granulation technology to make effervescent tablets and sachets that dissolve rapidly in water. The original promoters still run operations. - **Two plants with international approvals** - the Nashik facilities can produce six million effervescent tablets and one million sachets a month, and hold WHO cGMP and FSSAI certifications, which lets SciTech export to more than 20 countries. Over half its revenue comes from overseas customers. - **A niche that sits alongside the enzyme business** - the segment serves animal-health, pharma and nutraceutical clients, meaning it can manufacture for the same end-markets the parent already knows, but earns a contract-manufacturing fee rather than selling its own branded ingredients. # R&D and regulatory engine **Seven labs on three continents, over 100 scientists, and a regulatory-dossier track record that opens doors in Europe and North America - the shared capability that feeds every business segment.** - **Strain discovery and enzyme engineering** - the company uses AI-based in-silico screening to identify promising enzyme variants, then validates them in wet labs, and has built diverse enzyme libraries for biocatalysis, sugar management, protein digestion and animal nutrition. A proprietary technology for high-density cultivation of Bacillus coagulans came out of the Sinnar R&D centre. - **Regulatory approvals as a competitive moat** - the company has filed 17 food-enzyme dossiers with the European Food Safety Authority (13 received a positive opinion) and 10 GRAS dossiers with the US FDA (7 received no-question letters). These filings take years and cost significant money, so they create a barrier that smaller competitors struggle to cross. - **A new R&D centre coming online** - a state-of-the-art facility on 15 acres in Nashik is expected to become fully operational in the latter half of this fiscal year, expanding the company’s capacity to develop and scale new enzymes. # Group structure and partners **A listed Indian parent with a web of subsidiaries that give it manufacturing scale, US and European market access, and specialised technology - all funded internally with almost no debt.** - **The parent company** - Advanced Enzyme Technologies Ltd is listed on the BSE and NSE, with promoters holding 43% and institutional investors including OrbiMed (12%) and Nalanda India Equity Fund (8%). - **North American reach through a wholly-owned chain** - Advanced Enzymes USA owns Specialty Enzymes and Biotechnologies (SEB), a California-based producer with over 25 probiotic strains and certifications from NSF, Organic and Non-GMO Project, plus Enzyme Innovation for industrial enzymes and AST for consumer supplements. - **European technology through evoxx** - the German subsidiary evoxx technologies, held via a Dutch intermediate, provides “Directed Evolution” technology for creating custom enzyme molecules and employs around 40 scientists. - **Indian manufacturing subsidiaries** - JC Biotech (96% owned) runs a fermentation plant in Ongole that also makes Serratiopeptidase; SciTech Specialities (51% owned) handles effervescent contract manufacturing; Advanced Bio-Agro Tech (60% owned) focuses solely on animal-nutrition enzymes for poultry and cattle. - **Almost debt-free and internally funded** - the group has a debt-to-equity ratio of 0.01x and funds all operations through internal accruals, with a Crisil A+/Stable long-term credit rating.